Functional Neuromodulation Ltd. (FNM) is dedicated to advancing the application of deep brain stimulation (DBS) therapies to help improve the lives of people with Alzheimer’s and other memory and cognitive disorders. The company, founded in 2010 by Andres Lozano, MD, scientific founder and principal inventor; and Dan O’Connell, co-founder and founding CEO, is investigating the use of DBS of the fornix (DBS-f) to drive neural activity and modulate the brain’s memory circuit. FNM has raised a total of $13.4 in funding commitments from Genesys Capital, Foundation Medical Partners and Medtronic, Inc. Building on early clinical data, the company has initiated the ADvance Study, a multi-center feasibility study of DBS-f in patients with mild Alzheimer’s disease. Enrollment of ADvance was completed in April 2014, and top-line outcomes data are expected in mid-2015. The ADvance Study is also supported through a translational grant of up to $2.75M from the National Institute on Aging, part of the National Institutes of Health.
CAUTION — Investigational device. Limited by Federal law to investigational use.
Functional Neuromodulation, Ltd. | 2 Oliver St., Suite 61 | Boston, MA 02109 | firstname.lastname@example.org | 1-866-296-4040
© 2015 Functional Neuromodulation Ltd. All rights reserved.